Tempus AI has set August 8, 2025 as the date when it will open its books for the second quarter and put Founder–CEO Eric Lefkofsky and CFO Jim Rogers on the line at 8 a.m. ET to field investor questions. The schedule matters because the company is still only a little more than a year removed from its IPO and every earnings print has served as a referendum on whether its massive genomic data repository and AI‑driven diagnostics platform can translate into sustainable commercial momentum.
Street expectations heading into the call are strikingly uniform. Consensus estimates suggest a loss of roughly $0.23 per share on revenue near $297 million. The revenue range runs from about $287 million to a top-end $303 million. If Tempus lands in the middle of that band, it would mark year-over-year top-line growth of about 80 percent, keeping intact the company’s pattern of posting the fastest revenue acceleration in the genomics-diagnostics cohort.
That momentum was on full display last quarter, when Tempus posted $255.7 million in Q1 sales—up 75 percent from the prior-year period—and beat consensus by a healthy margin. Management’s operational discipline also showed up in the figures: gross margin expanded and the EPS loss of $0.24 came in narrower than analysts expected, underscoring an improving glide path toward profitability even as the company absorbs Ambry Genetics and invests heavily in AI tools such as Tempus One.
Those beats emboldened management to lift full-year 2025 revenue guidance to approximately $1.25 billion and to project a swing to slightly positive adjusted EBITDA—a notable milestone for a firm that still reports GAAP net losses north of $700 million but is rapidly closing the gap between growth and cash burn. Investors will therefore listen closely on the call for any traction updates on margin-accretive data and services deals, as well as clarity on whether further guidance raises are on the table.
Operational color should come against a backdrop of encouraging trends. A richer mix of high-margin data licensing, broader uptake of minimal-residual-disease (MRD) assays, and continued scaling of the Ambry lab network are already lifting gross profit faster than revenue. Every incremental percentage point of margin expansion makes the long-promised flywheel of data, AI insights, and clinical utility more believable—and more valuable—for both biopharma customers and payers.
The equity market has taken notice. Analysts largely maintain a “Buy” or “Strong Buy” rating, and their average twelve‑month target of around $65 implies single-digit upside from the current share price, with more bullish targets stretching toward $75. The stock’s 52-week range, from $31 to $91, is a reminder that sentiment can swing sharply depending on whether earnings exceed or disappoint.
Many analysts who initiated coverage after the IPO remain confident that the company’s differentiated data asset, combined with significant tailwinds in precision oncology and broader AI adoption across healthcare, can support compound annual growth rates in excess of 25 percent well into the back half of the decade. Still, Tempus needs to prove its ability to consistently generate cash while navigating a competitive and highly scrutinized genetic-testing space.
Friday’s release is shaping up as a critical checkpoint: another beat-and-raise quarter would go a long way toward validating Tempus AI’s claim that it can achieve scale advantages faster than its peers, while any stumble on revenue growth, margin progression, or cash-flow guidance could reignite concerns about whether its ambitious AI roadmap can outrun the capital demands of building a category-defining platform in precision medicine.